Based on data from multiple clinical trials, the FDA has approved obinutuzumab for the treatment of adults with lupus nephritis in combination with standard therapy.
Study Finds Baricitinib Is Effective in Patients with Takayasu Arteritis
A small study shows baricitinib effectively treats refractory Takayasu arteritis & allows for glucocorticoid reduction with no serious adverse events recorded.
Prednisone or Methotrexate for Pulmonary Sarcoidosis?
The recently released PREDMETH study results indicate that methotrexate can be considered a real alternative to prednisone for patients with pulmonary sarcoidosis.
The Great Pediatric Debate—Corticosteroids in SLE: Slay or Stay?
Long-term use of corticosteroids is associated with numerous adverse effects, particularly in children, but guidance is lacking on how to manage low-dose prednisone in clinically quiescent disease. In The Great Debate at ACR Convergence 2025—Corticosteroids in Pediatric SLE: Slay or Stay, two pediatric lupus experts took to the stage to explore this important topic.
EU Recommends Approval of Anifrolumab Auto-Injector
Research demonstrating the effectiveness of subcutaneous anifrolumab-fnia as an auto-injector in patients with active systemic lupus erythematosus is the basis of a recent decision in the EU to recommend the treatments approval for this patient population.
Rethinking Lupus Nephritis: Are Current Approaches & Guidelines off Target?
A rheumatologist & lupus expert reviews lupus nephritis treatment, questioning proteinuria cutoffs & ACR guidelines, advocating for newer therapies & end-of-treatment biopsies.
Hydroxychloroquine Remains a Mainstay in Lupus Nephritis
New data: HCQ reduces risk of eGFR decline by 61–73% & slows kidney function loss. Early initiation is critical for renal health in lupus nephritis.
2024 ACR Guideline for the Screening, Treatment & Management of Lupus Nephritis
Review 28 recommendations covering proteinuria screening, biopsy indications & triple therapy regimens for lupus nephritis.
Obinutuzumab Aids Standard Therapy for Lupus Nephritis
Phase 3 REGENCY data: Obinutuzumab & standard therapy improve complete renal response rates in active lupus nephritis patients.
FDA Approvals: Lupus Nephritis
Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…
- 1
- 2
- 3
- …
- 127
- Next Page »